Difficult reactions to psychedelics range from transient fear during intoxication to symptoms that continue after the acute drug effects have ended. Persistent anxiety, altered perception, dissociation and deterioration in mood deserve careful assessment. They should neither be dismissed as inevitable healing nor assumed to represent permanent damage.
A challenging experience can sometimes be understood constructively, but worsening symptoms are not proof that treatment is working. Severe or persistent difficulties require assessment and a clear route into appropriate care.
On this page
Acute difficulty and prolonged symptoms are distinct
During the acute experience, fear, confusion and emotional intensity may occur alongside altered perception. The immediate clinical task is to assess safety, provide appropriate support and identify medical or psychiatric complications. Symptoms that persist after intoxication has ended create a different clinical problem, requiring attention to their course and impact.
Observational work on challenging experiences has linked certain coping responses with reported emotional breakthrough. Those associations do not show that distress causes recovery or that someone should be pressured to endure an overwhelming experience. Fear-related challenges were negatively associated with breakthrough in one mixed-methods investigation, illustrating the limits of treating all difficulty as therapeutic.1
The absence of a serious adverse event classification also does not mean the absence of important harm. In a 2026 depression trial, two psilocybin recipients developed persistent, severe anxiety requiring medical attention, although no drug-related serious adverse events were reported.2
Recognising different patterns of difficulty
| Presentation | What needs clarification | Interpretation to avoid |
|---|---|---|
| Anxiety or panic | Duration, triggers, sleep, avoidance and physical symptoms | That more emotional intensity necessarily means more progress |
| Depersonalisation or derealisation | Feelings of detachment, preserved insight and functional impact | That a sense of unreality automatically establishes psychosis |
| Persistent visual phenomena | Nature of symptoms, distress and alternative causes | That any afterimage proves HPPD |
| Marked mood or behavioural change | Depression, agitation, reduced need for sleep, unusual beliefs and risk | That an uplifting or spiritual explanation rules out illness |
Depersonalisation concerns detachment from oneself; derealisation concerns a sense that the surroundings are unreal or altered. A person may recognise that the feeling is a change in experience rather than believe the world has literally ceased to exist. Assessment should explore that distinction without arguing about the person’s account or imposing a metaphysical explanation.
Accounts of prolonged difficulties describe anxiety, disconnection, altered self-experience and uncertainty about reality or meaning. These experiences can disrupt relationships, employment and confidence even when the person remains able to describe them coherently. The clinical significance depends on distress, impairment and risk, not on whether the experience sounds unusual to an observer.34
Persistent perceptual symptoms and HPPD
Hallucinogen persisting perception disorder, or HPPD, concerns recurrent or continuing perceptual symptoms after intoxication, accompanied by clinically significant distress or impairment and not better explained by another condition. Described visual phenomena include afterimages, trails behind moving objects, altered colours and visual snow. A symptom checklist alone is insufficient for diagnosis.5
A prospective naturalistic study enrolled 654 people before planned psychedelic use, but only 212 continued to the four-week endpoint. Of those 212, 68 reported at least one HPPD-like effect and two described distress from those effects. This was a self-selected, mixed-drug sample with substantial attrition, and its questionnaire findings were not clinician-confirmed HPPD diagnoses.6
Quoting the 32.1% symptom figure as the incidence of HPPD would therefore be misleading. Quoting the small number reporting distress as proof that persistent difficulties are negligible would also be unjustified. Symptoms, diagnosable disorder and severe functional impairment are different outcomes, and missing participants introduce uncertainty in either direction.
A neuro-ophthalmological case series described 13 people with HPPD; investigations were mostly normal. Normal examination or imaging findings do not invalidate the reported symptoms. They also do not remove the need to consider alternative explanations such as migraine, seizure-related phenomena, eye disease, medicines and other substance effects.5
What can be said about frequency?
The answer depends strongly on who was recruited and how difficulties were defined. A survey of 608 people specifically selected for extended difficulties describes the range and burden of those difficulties. It cannot estimate the proportion of all psychedelic users who will experience them.3
Similarly, a study that deliberately recruited negative experiences obtained 32 completed questionnaires and 15 detailed interviews. Anxiety and other persistent symptoms were prominent, but the investigators explicitly cautioned against inferring prevalence. Such accounts help identify problems that routine follow-up may miss; they do not provide a population risk calculator.4
Clinical trials usually involve screening, defined substances, supervision and selected participants. Naturalistic reports often involve several drugs, uncertain exposures and different environments. Neither body of evidence can be transferred unchanged to the other. A reliable estimate needs a clear denominator, systematic follow-up and consistent definitions.
Assessment should be practical and non-judgemental
A useful history includes the substance and any co-use, the timing of symptoms, previous psychiatric and neurological problems, sleep, prescribed medicines and recent medication changes. The clinician also needs to understand what happened around the experience, including interpersonal pressure, frightening events or possible boundary violations.
These questions should not become an investigation into whether the person used psychedelics correctly. Someone can need care regardless of whether use occurred in a study, a retreat, a training programme or an informal setting. The person’s interpretation can be heard while medical and psychological explanations remain open.
The NNDC consensus emphasises vulnerability, suggestibility and professional boundaries. A clinician’s spiritual or theoretical commitments should not determine whether a patient’s deterioration is recognised. Unusual experiences can be explored without treating them as verified memories, revelations or instructions that must be acted upon.7
Support and treatment
Support should address the most impairing problems and establish continuity of care. This may include restoring routines, reducing avoidable stress, addressing sleep and anxiety, and treating an identified psychiatric or neurological condition. A clinician can help someone discuss an experience without recommending another psychedelic exposure. Harm reduction and integration approaches explicitly distinguish supportive care from endorsement of further use.8
HPPD treatment evidence remains limited. A 2025 systematic review found mostly case reports, small case series and observational medication studies, with no basis for a confidently established, universally effective drug regimen. Its reported recovery proportions cannot be treated as reliable individual prognoses. Medication selection requires clinical judgement, monitoring and attention to the possibility of worsening symptoms.9
A published case from an underground psilocybin training programme described severe deterioration after repeated exposures, including profound sleep impairment and suicidal thinking. Advice to avoid psychiatric help delayed treatment. The case cannot establish frequency or a treatment rule, but it illustrates why a commitment to a psychedelic explanatory model must not obstruct ordinary medical care.10
Immediate danger, inability to stay safe, marked confusion or rapidly escalating behavioural disturbance warrants emergency assessment. Persistent sleeplessness with agitation, worsening depression or psychotic symptoms also needs prompt professional review. These presentations should not wait for a routine integration appointment.117
Recovery without a prescribed narrative
Some people find personal meaning in a difficult experience; others primarily want symptoms to stop. Neither response should be imposed. Recovery can be assessed through improved sleep, concentration, relationships and daily functioning without requiring the person to describe the original experience as beneficial.
Follow-up should allow both improvement and continuing difficulties to be reported openly. Clear documentation, realistic expectations and access to appropriate care are more useful than promises of permanent damage or guaranteed transformation. Recognising harm is compatible with investigating therapeutic potential; it is part of making that investigation clinically credible.
References
- Wood MJ, McAlpine RG, Kamboj SK. Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study. Sci Rep. 2024;14:28817. doi:10.1038/s41598-024-79931-w.
- Yngwe H, Plavén-Sigray P, Ekman CJ, et al. Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial. JAMA Netw Open. 2026;9:e2612589. doi:10.1001/jamanetworkopen.2026.12589.
- Evans J, Robinson OC, Argyri EK, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS ONE. 2023;18:e0293349. doi:10.1371/journal.pone.0293349.
- Bremler R, Katati N, Shergill P, et al. Case analysis of long-term negative psychological responses to psychedelics. Sci Rep. 2023;13:15998. doi:10.1038/s41598-023-41145-x.
- Ford H, Fraser CL, Solly E, et al. Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature. Front Neurol. 2022;13:878609. doi:10.3389/fneur.2022.878609.
- Zhou K, de Wied D, Carhart-Harris RL, et al. Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use. PNAS Nexus. 2025;4:pgae560. doi:10.1093/pnasnexus/pgae560.
- Hosein MM, Reid MJ, Walser S, et al. Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. EClinicalMedicine. 2025;89:103517. doi:10.1016/j.eclinm.2025.103517.
- Gorman I, Nielson EM, Molinar A, et al. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front Psychol. 2021;12:645246. doi:10.3389/fpsyg.2021.645246.
- Neven A, Blom JD. Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review. Harv Rev Psychiatry. 2025;33:264-275. doi:10.1097/hrp.0000000000000439.
- Perna J, Trop J, Palitsky R, et al. Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report. BMC Psychiatry. 2025;25:184. doi:10.1186/s12888-024-06303-z.
- National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). Recommendations; accessed 11 October 2026.